Clinical Trials
49 trialsNCT02688803 2025-12-04
OTT15-04
Ottawa Hospital Research Institute
Phase 4 Terminated
NCT00253318 2025-04-27
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03393741 2024-06-25
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
University of Wisconsin, Madison
Terminated
NCT05207514 2024-05-17
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
Samyang Biopharmaceuticals Corporation
Phase 3 Terminated
NCT00665457 2023-09-13
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Phase 2 Terminated
NCT00251433 2023-03-31
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Novartis
Phase 1 Terminated
NCT05622058 2023-02-27
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Aileron Therapeutics, Inc.
Phase 1 Terminated
NCT02393248 2023-01-06
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
Phase 1/2 Terminated
NCT02229149 2022-12-02
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
US Oncology Research
Phase 2 Terminated
NCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
NCT03894007 2021-09-23
PREDIXIIHER2
Karolinska University Hospital
Phase 2 Terminated
NCT04031885 2021-08-24
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
Eli Lilly and Company
Phase 4 Terminated
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT00625898 2020-09-10
BETH
NSABP Foundation Inc
Phase 3 Terminated
NCT00979641 2019-03-28
AINO
Tampere University Hospital
Phase 2 Terminated
NCT00080626 2019-03-21
Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00063934 2019-03-05
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00584012 2018-10-19
A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer
University of Iowa
Phase 1 Terminated
NCT01690325 2018-08-13
Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)
West German Study Group
Phase 2 Terminated
NCT00852332 2018-07-24
Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
Centre Jean Perrin
Phase 2 Terminated
NCT02331251 2018-07-02
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
Phase 1/2 Terminated
NCT00864175 2018-01-18
Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer
Incyte Corporation
Phase 1/2 Terminated
NCT00832338 2017-08-31
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Emory University
Phase 2 Terminated
NCT02144012 2017-03-07
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer
Hoffmann-La Roche
Phase 3 Terminated
NCT00912444 2016-11-22
NATT
Shanghai Jiao Tong University School of Medicine
Phase 3 Terminated
NCT00845910 2016-11-02
A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT00546364 2016-03-10
IXTEND
R-Pharm
Phase 2 Terminated
NCT00636441 2015-12-11
Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer
Duke University
Phase 2 Terminated
NCT01985841 2015-10-08
Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00377780 2015-09-23
MYOHERTAX
Catharina Ziekenhuis Eindhoven
Phase 2 Terminated
NCT00539968 2015-02-05
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00511576 2015-01-08
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT00053911 2014-12-16
Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer
UNICANCER
Phase 3 Terminated
NCT00524459 2014-08-29
Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00576901 2014-08-11
A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
Hoffmann-La Roche
Phase 2 Terminated
NCT00118053 2013-11-20
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00104624 2013-09-04
Docetaxel in Treating Older Women With Metastatic Breast Cancer
UNICANCER
Phase 2 Terminated
NCT01301040 2013-08-30
Early Cardiac Toxicity of Adjuvant CT in Elderly BC.
Jules Bordet Institute
Phase 2 Terminated
NCT00476827 2013-07-17
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Duke University
Phase 2 Terminated
NCT00206453 2013-02-05
Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer
Baylor Breast Care Center
Phase 2 Terminated
NCT00025493 2013-01-24
S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer
SWOG Cancer Research Network
Phase 2 Terminated
NCT00288444 2012-12-18
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Emory University
Phase 1 Terminated
NCT00479856 2012-06-05
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT00343512 2012-04-27
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00453635 2012-03-13
Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00028483 2011-10-24
Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
Seagen Inc.
Phase 2 Terminated
NCT00193024 2011-05-03
Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00620100 2009-06-03
To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent
Sanofi
Phase 2 Terminated
NCT00225056 2007-04-20
Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma
Oncology Specialties, Alabama
Phase 2 Terminated